Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 376 participants.
Also called NCT01876368
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 376 participants
- Sponsor
- Registry
-
NCT01876368 -
2013-001783-36
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Guatemala, Philippines, Puerto Rico, Russia, Spain
- Registry status
- Completed
Technical summary
Registry record NCT01876368. Randomized; double masking; primary purpose treatment. Start 2013-09 (registry gives no type); primary completion 2014-08 (actual). Results posted on 2015-12-07.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
- Condition
- Hypertension
- Intervention (Drug)
- LCZ696
- Intervention (Drug)
- Olmesartan
- Intervention (Drug)
- Placebo of LCZ696
- Intervention (Drug)
- Placebo of Olmesartan
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct01876368- Content hash
5c4923eac9f85ab71f1ba8b1231a5af0dd971bde392b81d96b4c2694c514df51